NCT03946085 (AMD) is a NA clinical trial of Lumega-Z in Retinal Drusen, sponsored by Guardion Health Sciences, Inc..

Who is sponsoring NCT03946085?

NCT03946085 is sponsored by Guardion Health Sciences, Inc..

What drugs are being tested in NCT03946085?

Interventions in NCT03946085: Lumega-Z, AREDS2.

What condition does NCT03946085 study?

NCT03946085 studies Retinal Drusen, Age-related Macular Degeneration, Macular Degeneration.

Is NCT03946085 still recruiting?

NCT03946085 is currently completed. Last updated 10 May 2019.

Last reviewed 2019-05-10 · How we verify

NCT03946085: AMD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)

Completed NA Last updated 10 May 2019

What this trial tests

NA trial testing Lumega-Z in Retinal Drusen in 79 participants. Completed in 1 November 2018.

Timeline

19 January 2018

Primary endpoint
23 October 2018

1 November 2018

Quick facts

Lead sponsor	Guardion Health Sciences, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	79
Start date	19 January 2018
Primary completion	23 October 2018
Estimated completion	1 November 2018
Sites	1 location across United States

Drugs / interventions tested

Lumega-Z
AREDS2

Conditions studied

Retinal Drusen — all drugs for Retinal Drusen →
Age-related Macular Degeneration — all drugs for Age-related Macular Degeneration →
Macular Degeneration — all drugs for Macular Degeneration →

Sponsor

Guardion Health Sciences, Inc.

Who can join

18 and older, any sex, with Retinal Drusen or Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the clinical benefits in visual function from dietary supplementation of the Lumega-Z carotenoid liquid-supplement in participants with drusen and at risk of AMD. The effects of Lumega-Z supplementation will be compared to an active comparator, the AREDS2 multivitamin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03946085 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guardion Health Sciences, Inc.
Last refreshed: 10 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03946085.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing